Samsung Biologics' Accounting Violation's Impact on Samsung C&T and Rest of the Korean Pharmas
On May 1st, 2018, Korea's Financial Supervisory Service (FSS) announced that Samsung Biologics Co., Ltd (207940 KS) violated accounting rules after...
393 Views
Foreign Investors Vs. Local Institutions in Korean Stock Market - Who Is Right?
Last month, foreign investors went on a buying spree in the Korea's second largest stock market, KOSDAQ. In contrast, they went on a selling spree...
1.3k Views
How Will South Korea Change With Moon as Its Next President? (Top 10 Issues)
Bonifas and Barrett may not be household names to most people. They were two US Army officers stationed in South Korea who were killed by North...
509 Views
MediSetter Interview:Â Insight on Opportunities in Asia's Healthcare Industry
Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...
4.2k Views
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.6k Views